ABSTRACT: A randomised, parallel-group clinical study was undertaken to compare the efficacy of Celestamine tablet, Celestone tablet, Celestone 1/2 tablet and Polaramine tablet in allergic skin disorders of at least a moderate severity. Either drug was administered thrice daily for 14 days. Every patient reported for clinical examination and evaluation four times viz. just before starting therapy (Day 0) and at the end of 2,7 and 14 days' treatment. Clinical improvement in the individual symptoms on a 4-point scale and the total symptom score were used to compare the efficacy. Out of the 323 patients successfully completing this study there were 84,82,79 and 78 respectively on each drug. Every drug produced a statistically progressive improvement during each of the three follow-up visits. However, Celestamine tablet or Celestone tablet was significantly superior to the individual components of the former. Celestamine offers a synergistic and steroidsparing effect. No adverse effects were reported by any patient in this study.

[ABSTRACT]   Full text not available   

ABSTRACT: The safety, efficacy and cosmetic acceptability of Sisomicin cream and Neosporin ointment were evaluated in a randomised. parallel-group clinical study utilising the blind-evaluator technique. Either preparations was applied twice a day for one week in patients with primary pyodermas, Such a comparative study does not appear to have been reported so far. Both the preparations were safe. Ensamycin cream was significantly more effective than Neosporin ointment and also had a better cosmetic acceptability.

[ABSTRACT]   Full text not available   

ABSTRACT: The efficacy and safety of mometasone furoate 0.1 percent cream, a formulation of a new non-fluorinated topical steroid, were evaluated in comparison with those of betamethasone valerate 0.12 percent cream. Both creams were applied twice-daily for 21 days in this randomised, double-blind, parallel- group clinical study. One hundred thirty-five patients (68 plus 67) of moderate to severe dermatoses completed the study. Three cardinal signs (erythema, induration, pruritus) together with physician's global evaluation during each weekly follow-up were the criteria of efficacy. Both drugs were efficacious in treating dermatoses. However, mometasone furoate was significantly more effective as compared to betamethasone valerate. Only one patient in each treatment group showed an adverse drug effect.

[ABSTRACT]   Full text not available   

ABSTRACT: In a double-blind study, betamethasone dipropionate (0.05 percent) and betamethasone valerate (0.12 percent) were randomly evaluated in eczemas and other steriod-responsive dermatoses. The former was dispensed in a propylene glycol vehicle, while the latter had the usual non-greasy ointment basic. The improvement was assessed by the reduction in erythema, induration and pruritus in the course of 3 weeks. It was apparent from the analysis of the data that the preceding parameters in patients on Cream-A showed a statistically significant improvement over those receiving Cream-B week by week. Further the overall assessment showed a remarkable response in patients in patients on Cream-A. The side effects of Cream-A included transient sensation of burning or stinging. The Cream-B in addition, caused local swelling, pain and pruritus in some of the patients.

[ABSTRACT]   Full text not available   

ABSTRACT: A multicentric study was conducted to determine the sensitization potential of sisomicin sulphate 0.1 percent cream. During this first study of its kind it was found that this new topical antibiotic cream has a very low potential to cause skin sensitization. Only 0.64 percent of test sites had a weak positive reaction on the "Patch Test" after 4 days of application of the patch.

[ABSTRACT]   Full text not available   

ABSTRACT: A clinical study is undertaken to evaluate the effectiveness of Interferon (IFN) alpha-2b (rbe) in genital warts. This IFN alpha-2b is produced from bacteria (Escherichia coli) genetically modified by recombinant DNA technology. The treatment schedule consists of the subcutaneous injection of 1x10 6 I.U. IFN alpha-2b 3 times weekly perilesionally. Therapy is given for 10 injections. In some patients the course is repeated and is some upto 2x10 6 I.U. IFN is given in one sitting. All patients are evaluated with reference to age, sex, site, number and size of the lesions, The injection is tolerated well by the patients and none of them show side effects like flu like syndrome with nausea and vomiting, altered liver and renal functions, cardiovascular complications, neurological abnormalities and bone marrow depression. The results are very much encouraging and complete clearance of the warts to excellent response occurred in all patients. In some, even adjacent warts which are not injected also show signs of resolution and clearing. It is concluded that interferon alpha-2b is a very useful therapy for genital warts.

[ABSTRACT]   Full text not available